Hepion Pharmaceuticals, Inc. 8-K

What Happened Hepion Pharmaceuticals, Inc. (HEPA) filed an 8-K (Item 5.02) reporting that on July 1, 2026 the company’s Board of Directors approved the immediate appointment of Danina Fisher and Gary S. Stetz, II as directors of the company.

Key Details

• Appointments approved by the Board effective July 1, 2026; 8-K filed July 2, 2026.
• New directors: Danina Fisher and Gary S. Stetz, II.
• The filing states there are no arrangements or understandings between either new director and any other person regarding their selection.
• The filing notes no family relationship between Ms. Fisher and Mr. Stetz, and separately states that Mr. Stetz is the son of Gary Stetz.

Why It Matters Board membership changes affect corporate governance and oversight. Investors should note the change in Hepion’s board composition and watch for any future disclosures about the directors’ roles, committee assignments, compensation or potential related‑party matters connected to the noted family relationship.